+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence



Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence



Journal of Clinical Oncology 21(17): 3377; Author Reply 3377-8




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050832518

Download citation: RISBibTeXText

PMID: 12947081

DOI: 10.1200/jco.2003.99.006


Related references

Management of Asymptomatic Anthracycline-Induced Cardiac Damage After Treatment for Childhood Cancer. Journal of Pediatric Hematology/Oncology 27(6): 319-322, 2005

Screening for Anthracycline-Related Cardiac Dysfunction in Childhood Cancer Survivors: Can Less be More?. Pediatric Blood and Cancer 62(12): 2067-2068, 2016

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clinical Cancer Research 20(24): 6314-6323, 2015

The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of Oncology 23(8): 2191-2198, 2012

Management of asymptomatic anthracycline-induced cardiac damage after treatment for childhood cancer: a postal survey among Dutch adult and pediatric cardiologists. Journal of Pediatric Hematology/Oncology 27(6): 319-322, 2005

Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 48(3): 313-320, 2006

Low-dose dobutamine echo stress test for the evaluation of cardiac function in asymptomatic childhood cancer survivors treated years before with anthracycline. European Heart Journal 19(ABST SUPPL ): 312, 1998

Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. Clinical Cancer Research 24(13): 3119-3125, 2018

Late cardiac effects of anthracycline therapy for childhood cancer Left ventricular systolic dysfunction in asymptomatic patients. European Heart Journal 16(ABSTR SUPPL ): 509, 1995

Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors. Journal of Pediatric Hematology/Oncology 32(5): 411-415, 2010

Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography 35(2): 234-240, 2017

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatric Cardiology 34(4): 826-834, 2013

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. Journal of Cancer Survivorship 8(2): 183-189, 2015

Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors. Pediatric Blood and Cancer 57(3): 467-472, 2011

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database of Systematic Reviews 2011(9): Cd008011, 2011